Merck cancer drug improves survival in phase 3 trial

Advertisement

Merck’s experimental cancer drug sacituzumab tirumotecan significantly improved overall survival in patients with advanced gastroesophageal cancer in a phase 3 trial.

The TroFuse-015 trial enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two previous lines of systemic therapy. Patients receiving the antibody-drug conjugate, also known as sac-TMT, had significantly improved overall survival compared with those receiving treatment selected by their physicians, according to a Nov. 20 news release. 

However, the drug did not significantly improve progression-free survival. A secondary measure of tumor response was not formally tested under the trial’s prespecified analysis plan. Merck did not disclose detailed survival data and reported no new safety concerns.

The drug, licensed from Kelun-Biotech, targets the TROP2 protein found on cancer cells. It is approved for four indications in China and is under FDA priority review for previously treated endometrial cancer, with a decision expected by June 2027.

Merck plans to share the trial findings with regulators and present detailed results at an upcoming medical conference. The study is part of an 18-trial phase 3 development program evaluating sac-TMT across several cancer types.

Advertisement

Next Up in Pharmacy

Advertisement